NASDAQ:SPRB Spruce Biosciences Q3 2024 Earnings Report $52.92 +0.28 (+0.53%) Closing price 08/17/2026 04:00 PM EasternExtended Trading$52.00 -0.92 (-1.74%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Spruce Biosciences EPS ResultsActual EPS-$15.75Consensus EPS -$20.25Beat/MissBeat by +$4.50One Year Ago EPSN/ASpruce Biosciences Revenue ResultsActual Revenue$0.60 millionExpected Revenue$1.80 millionBeat/MissMissed by -$1.20 millionYoY Revenue GrowthN/ASpruce Biosciences Announcement DetailsQuarterQ3 2024Date11/11/2024TimeBefore Market OpensConference Call DateMonday, November 11, 2024Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Spruce Biosciences Earnings HeadlinesSpruce Biosciences Inc.August 16 at 7:06 PM | marketwatch.comCitizens Jmp Has Lowered Expectations for Spruce Biosciences (NASDAQ:SPRB) Stock PriceAugust 15 at 3:13 AM | americanbankingnews.comThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the project. Unocal and Texaco did the same. All three buried the results because it threatened their core business. Now one company has spent sixty years developing what Big Oil refused to touch. Google locked in a 15-year contract, Bill Gates wrote a $100 million check, and on August 18th the government hands it a competitive edge no other energy source receives.August 18 at 1:00 AM | Behind the Markets (Ad)Spruce Biosciences (NASDAQ:SPRB) Cut to "Strong Sell" at Wall Street ZenAugust 15 at 2:13 AM | americanbankingnews.comCure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce BiosciencesAugust 12, 2026 | finance.yahoo.comSpruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical DevelopmentAugust 3, 2026 | finance.yahoo.comSee More Spruce Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spruce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spruce Biosciences and other key companies, straight to your email. Email Address About Spruce BiosciencesSpruce Biosciences (NASDAQ:SPRB) is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials. The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels. In parallel, Spruce is developing nevanimibe, an adrenocortical hormone synthesis inhibitor, to further address the hormonal imbalances associated with CAH. Both candidates have demonstrated promising safety and efficacy profiles in early-phase studies. Since its founding in 2017, Spruce Biosciences has established a global clinical infrastructure with trial sites across North America and Europe, enabling the company to enroll patients in its pivotal studies efficiently. The company collaborates with academic centers and patient advocacy groups to support trial design and patient recruitment, underscoring its commitment to advancing care for individuals living with rare endocrine disorders. Under the leadership of President and Chief Executive Officer Jonathan Porges, Spruce combines experienced management with a scientific advisory board comprised of experts in endocrinology and drug development. The company’s deliberate strategy of targeting well-defined patient populations aims to streamline regulatory pathways and bring transformative therapies to market for communities with few existing treatment options.View Spruce Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Birkenstock Beats the Skeptics—But Not on EPSThese 5 Dividend Stocks Show Why Income Investing Still MattersThe Quantum Race Is Heating Up—And 2 Small Players Stand OutMarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsLooking Beyond CrowdStrike? 3 AI Security Stocks Stand Out5 Recession-Proof Stocks Hiding in Cardboard Boxes Upcoming Earnings Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026)Walmart (8/20/2026)Deere & Company (8/20/2026)PDD (8/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
